title: Cancer testis antigen and immunotherapy.
abstract: The identification of cancer testis (CT) antigens has been an important advance in determining potential targets for cancer immunotherapy. Multiple previous studies have shown that CT antigen vaccines, using both peptides and dendritic cell vaccines, can elicit clinical and immunologic responses in several different tumors. This review details the expression of melanoma antigen family A, 1 (MAGE-A1), melanoma antigen family A, 3 (MAGE-A3), and New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in various malignancies, and presents our current understanding of CT antigen based immunotherapy.
authors.affiliation: Department of Pediatrics, Division of Hematology/Oncology, University of Louisville, KY, USA.
authors.forename: Deepa Kolaseri
authors.initials: DK
authors.lastname: Krishnadas
authors.affiliation: Department of Pediatrics, Division of Hematology/Oncology, University of Louisville, KY, USA.
authors.forename: Fanqi
authors.initials: F
authors.lastname: Bai
authors.affiliation: Department of Pediatrics, Division of Hematology/Oncology, University of Louisville, KY, USA.
authors.forename: Kenneth G
authors.initials: KG
authors.lastname: Lucas
keywords: cancer testis antigens; immunotherapy; vaccine